OncoMatch/Clinical Trials/NCT04587687
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Is NCT04587687 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Bendamustine Hydrochloride and Brentuximab Vedotin for recurrent follicular lymphoma.
Treatment: Bendamustine Hydrochloride · Brentuximab Vedotin — This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TNFRSF8 expression >1% (>1% (tumor cells or surrounding peripheral microenvironment))
follicular CD30+ non-Hodgkin lymphoma (NHL)... CD30 positivity > 1% (tumor cells or surrounding peripheral microenvironment)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received:
Relapsed or refractory disease after at least 1 prior regimen, defined using the 2014 Lugano classification
Cannot have received: bendamustine (bendamustine)
Exception: allowed if no progression within 6 months of receiving treatment
Prior therapy with bendamustine or a bendamustine-containing regimens with progression within 6 months of receiving treatment
Lab requirements
Blood counts
Leukocytes >= 2,500/mcL; Absolute neutrophil count >= 1,000/mcL; Platelets >= 50,000/mcL; Hemoglobin >= 8 g/dL
Kidney function
Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault
Liver function
Total bilirubin <= 1.5 x ULN (<= 3 x ULN for Gilbert disease); AST/ALT <= 3 x ULN (<= 5 x ULN for patients with liver involvement); Alkaline phosphatase <= 2.5 x ULN (<= 5 x ULN for patients with documented liver involvement or bone metastases)
Leukocytes >= 2,500/mcL; Absolute neutrophil count >= 1,000/mcL; Platelets >= 50,000/mcL; Hemoglobin >= 8 g/dL; Total bilirubin <= 1.5 x ULN (however, patients with known Gilbert disease who have serum bilirubin level <= 3 x ULN may be enrolled); AST/ALT <= 3 x ULN (<= 5 x ULN for patients with liver involvement); Alkaline phosphatase <= 2.5 x ULN (<= 5 x ULN for patients with documented liver involvement or bone metastases); Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify